GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  Magee, Michael S ^a,b   Kraft, Crystal L ^b   Abraham, Tara S ^b   Baybutt, Trevor R ^b   Marszalowicz, Glen P ^c   Li, Peng ^d   Waldman, Scott A ^b   Snook, Adam E ^b  

^a BLUEBIRD BIO   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DREXEL UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; chimeric antigen receptors; colorectal cancer; gene therapy; guanylyl cyclase C

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GREEN FLUORESCENT PROTEIN; GUANYLATE CYCLASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE THERAPY; HISTOPATHOLOGY; MALE; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WHOLE BODY RADIATION;

EID: 84990946588     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1227897     Document Type: Article

References (53)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
2. J.Couzin-Frankel. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
3. M.E.Dudley, J.R.Wunderlich, P.F.Robbins, J.C.Yang, P.Hwu, D.J.Schwartzentruber, S.L.Topalian, R.Sherry, N.P.Restifo, A.M.Hubicki et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
4. S.A.Grupp, M.Kalos, D.Barrett, R.Aplenc, D.L.Porter, S.R.Rheingold, D.T.Teachey, A.Chew, B.Hauck, J.F.Wright et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa12-15134
5. D.L.Porter, B.L.Levine, M.Kalos, A.Bagg, C.H.June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
6. C.U.Louis, B.Savoldo, G.Dotti, M.Pule, E.Yvon, G.D.Myers, C.Rossig, H.V.Russell, O.Diouf, E.Liu et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx.doi.org/10.1182/blood-2011-05-354449
7. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
8. M.R.Parkhurst, J.C.Yang, R.C.Langan, M.E.Dudley, D.A.Nathan, S.A.Feldman, J.L.Davis, R.A.Morgan, M.J.Merino, R.M.Sherry et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19:620-6; PMID:21157437; http://dx.doi.org/10.1038/mt.2010.272
9. Y.Zhao, Q.J.Wang, S.Yang, J.N.Kochenderfer, Z.Zheng, X.Zhong, M.Sadelain, Z.Eshhar, S.A.Rosenberg, R.A.Morgan. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183:5563-74; PMID:19843940; http://dx.doi.org/10.4049/jimmunol.0900447
10. M.R.Parkhurst, J.Joo, J.P.Riley, Z.Yu, Y.Li, P.F.Robbins, S.A.Rosenberg. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 2009; 15:169-80; PMID:19118044; http://dx.doi.org/10.1158/1078-0432.CCR-08-1638
11. J.H.Sampson, B.D.Choi, L.Sanchez-Perez, C.M.Suryadevara, D.J.Snyder, C.T.Flores, R.J.Schmittling, S.K.Nair, E.A.Reap, P.K.Norberg et al. EGFRvIII mCAR-modified T-Cell therapy cures mice with established intracerebral glioma and generates host immunity against Tumor-Antigen loss. Clin Cancer Res 2014; 20:972-84; PMID:24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
12. J.N.Kochenderfer, Z.Yu, D.Frasheri, N.P.Restifo, S.A.Rosenberg. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-86; PMID:20631379; http://dx.doi.org/10.1182/blood-2010-01-265041
13. E.Tran, D.Chinnasamy, Z.Yu, R.A.Morgan, C.C.Lee, N.P.Restifo, S.A.Rosenberg. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210:1125-35; PMID:23712432; http://dx.doi.org/10.1084/jem.20130110
14. G.S.Frick, G.M.Pitari, D.S.Weinberg, T.Hyslop, S.Schulz, S.A.Waldman. Guanylyl cyclase C:a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5:701-13; PMID:16149873; http://dx.doi.org/10.1586/14737159.5.5.701
15. S.L.Carrithers, M.T.Barber, S.Biswas, S.J.Parkinson, P.K.Park, S.D.Goldstein, S.A.Waldman. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A 1996; 93:14827-32; PMID:8962140; http://dx.doi.org/10.1073/pnas.93.25.14827
16. A.E.Snook, L.C.Eisenlohr, J.L.Rothstein, S.A.Waldman. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther 2007; 82:734-9; PMID:17898707; http://dx.doi.org/10.1038/sj.clpt.6100369
17. R.Birbe, J.P.Palazzo, R.Walters, D.Weinberg, S.Schulz, S.A.Waldman. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005; 36:170-9; PMID:15754294; http://dx.doi.org/10.1016/j.humpath.2004.12.002
18. S.Schulz, T.Hyslop, J.Haaf, C.Bonaccorso, K.Nielsen, M.E.Witek, R.Birbe, J.Palazzo, D.Weinberg, S.A.Waldman. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 2006; 12:4545-52; PMID:16899600; http://dx.doi.org/10.1158/1078-0432.CCR-06-0865
19. A.N.Charney, R.W.Egnor, J.T.Alexander-Chacko, V.Zaharia, E.A.Mann, R.A.Giannella. Effect of E. coli heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001; 280:G216-21; PMID:11208543
20. − secretion in human gut. J Physiol 1994; 479(Pt 3):433-40; PMID:7837099; http://dx.doi.org/10.1113/jphysiol.1994.sp02-0307
21. A.Guarino, M.B.Cohen, G.Overmann, M.R.Thompson, R.A.Giannella. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci 1987; 32:1017-26; PMID:3304888; http://dx.doi.org/10.1007/BF01297193
22. C.A.Hodson, I.G.Ambrogi, R.O.Scott, P.J.Mohler, S.L.Milgram. Polarized apical sorting of guanylyl cyclase C is specified by a cytosolic signal. Traffic 2006; 7:456-64; PMID:16536743; http://dx.doi.org/10.1111/j.1600-0854.2006.00398.x
23. H.R.Wolfe, M.Mendizabal, E.Lleong, A.Cuthbertson, V.Desai, S.Pullan, D.K.Fujii, M.Morrison, R.Pither, S.A.Waldman. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. J Nucl Med 2002; 43:392-9; PMID:11884500
24. K.Almhanna, T.Kalebic, C.Cruz, J.E.Faris, D.P.Ryan, J.A.Jung, T.Wyant, A.Fasanmade, W.A.Messersmith, J.Rodon. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res 2016; PMID:27178743; http://dx.doi.org/10.1158/1078-0432.ccr-15-2474
25. G.P.Marszalowicz, A.E.Snook, M.S.Magee, D.Merlino, L.D.Bertman-Booty, S.A.Waldman. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. OncoTarget 2014; 5:9460-71; PMID:25294806; http://dx.doi.org/10.18632/oncotarget.2455
26. A.E.Snook, M.S.Magee, S.Schulz, S.A.Waldman. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol 2014; 44:1956-66; PMID:24771148; http://dx.doi.org/10.1002/eji.201444539
27. A.E.Snook, P.Li, B.J.Stafford, E.J.Faul, L.Huang, R.C.Birbe, A.Bombonati, S.Schulz, M.J.Schnell, L.C.Eisenlohr et al. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res 2009; 69:3537-44; PMID:19351847; http://dx.doi.org/10.1158/0008-5472.CAN-08-3386
28. A.E.Snook, B.J.Stafford, P.Li, G.Tan, L.Huang, R.Birbe, S.Schulz, M.J.Schnell, M.Thakur, J.L.Rothstein et al. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst 2008; 100:950-61; PMID:18577748; http://dx.doi.org/10.1093/jnci/djn178
29. E.Robinson, A.Bartal, T.Mekori. Results of postoperative treatment of colorectal cancer by radiotherapy, chemotherapy and immunotherapy. Recent Results Cancer Res 1980; 75:80-7; PMID:7232842; http://dx.doi.org/10.1007/978-3-642-81491-4_13
30. A.Caruso, S.Licenziati, M.Corulli, A.D.Canaris, M.A.De Francesco, S.Fiorentini, L.Peroni, F.Fallacara, F.Dima, A.Balsari et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997; 27:71-6; PMID:9000587; http://dx.doi.org/10.1002/(SICI)1097-0320(19970101)27:1%3c71::AID-CYT-O9%3e3.0.CO;2-O
31. J.J.Mule, S.Shu, S.L.Schwarz, S.A.Rosenberg. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225:1487-9; PMID:6332379; http://dx.doi.org/10.1126/science.6332379
32. R.S.Chamberlain, M.W.Carroll, V.Bronte, P.Hwu, S.Warren, J.C.Yang, M.Nishimura, B.Moss, S.A.Rosenberg, N.P.Restifo. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996; 56:2832-6; PMID:8665522
33. L.Gattinoni, S.E.Finkelstein, C.A.Klebanoff, P.A.Antony, D.C.Palmer, P.J.Spiess, L.N.Hwang, Z.Yu, C.Wrzesinski, D.M.Heimann et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
34. S.A.Rosenberg, J.C.Yang, R.M.Sherry, U.S.Kammula, M.S.Hughes, G.Q.Phan, D.E.Citrin, N.P.Restifo, P.F.Robbins, J.R.Wunderlich et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
35. C.S.Hinrichs, N.P.Restifo. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013; 31:999-1008; PMID:24142051; http://dx.doi.org/10.1038/nbt.2725
36. H.J.Stauss, E.C.Morris. Immunotherapy with gene-modified T cells:limiting side effects provides new challenges. Gene Ther 2013; 20:1029-32; PMID:23804078; http://dx.doi.org/10.1038/gt.2013.34
37. M.E.Witek, K.Nielsen, R.Walters, T.Hyslop, J.Palazzo, S.Schulz, S.A.Waldman. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 2005; 11:8549-56; PMID:16361536; http://dx.doi.org/10.1158/1078-0432.CCR-05-1624
38. M.Chmielewski, O.Hahn, G.Rappl, M.Nowak, I.H.Schmidt-Wolf, A.A.Hombach, H.Abken. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012; 143:1095-107 e2; PMID:22750462; http://dx.doi.org/10.1053/j.gastro.2012.06.037
39. R.Bos, S.van Duikeren, H.Morreau, K.Franken, T.N.Schumacher, J.B.Haanen, S.H.van der Burg, C.J.Melief, R.Offringa. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68:8446-55; PMID:18922918; http://dx.doi.org/10.1158/0008-5472.CAN-08-1864
40. M.A.Valentino, J.E.Lin, A.E.Snook, P.Li, G.W.Kim, G.Marszalowicz, M.S.Magee, T.Hyslop, S.Schulz, S.A.Waldman. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest 2011; 121:3578-88; PMID:21865642; http://dx.doi.org/10.1172/JCI57925
41. M.Chmielewski, A.Hombach, C.Heuser, G.P.Adams, H.Abken. T cell activation by antibody-like immunoreceptors:increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004; 173:7647-53; PMID:15585893; http://dx.doi.org/10.4049/jimmunol.173.12.7647
42. H.Dai, Y.Wang, X.Lu, W.Han. Chimeric antigen receptors modified T-Cells for cancer therapy. J Natl Cancer Inst 2016; 108; PMID:26819347; https://dx.doi.org/10.1093/jnci/djv439
43. B.P.Babbitt, P.M.Allen, G.Matsueda, E.Haber, E.R.Unanue. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985; 317:359-61; PMID:3876513; http://dx.doi.org/10.1038/317359a0
44. F.Bar, C.Sina, G.Hundorfean, R.Pagel, H.Lehnert, K.Fellermann, J.Büning. Inflammatory bowel diseases influence major histocompatibility complex class I (MHC I) and II compartments in intestinal epithelial cells. Clin Exp Immunol 2013; 172:280-9; PMID:23574324; http://dx.doi.org/10.1111/cei.12047
45. P.Yu, M.T.Spiotto, Y.Lee, H.Schreiber, Y.X.Fu. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 2003; 197:985-95; PMID:12695490; http://dx.doi.org/10.1084/jem.20021804
46. A.Globerson-Levin, T.Waks, Z.Eshhar. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther 2014; 22:1029-38; PMID:24572294; http://dx.doi.org/10.1038/mt.2014.28
47. L.X.Wang, J.A.Westwood, M.Moeller, C.P.Duong, W.Z.Wei, J.Malaterre, J.A.Trapani, P.Neeson, M.J.Smyth, M.H.Kershaw et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010; 70:9591-8; PMID:21098715; http://dx.doi.org/10.1158/0008-5472.CAN-10-2884
48. E.J.Cheadle, R.E.Hawkins, H.Batha, A.L.O'Neill, S.J.Dovedi, D.E.Gilham. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010; 184:1885-96; PMID:20089697; http://dx.doi.org/10.4049/jimmunol.0901440
49. D.Chinnasamy, Z.Yu, M.R.Theoret, Y.Zhao, R.K.Shrimali, R.A.Morgan, S.A.Feldman, N.P.Restifo, S.A.Rosenberg. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120:3953-68; PMID:20978347; http://dx.doi.org/10.1172/JCI43490
50. H.J.Stauss, E.C.Morris. Immunotherapy with gene-modified T cells:limiting side effects provides new challenges. Gene Ther 2013; 20(11):1029-32; PMID:23804078; https://dx.doi.org/10.1038/gt.2013.34
51. X.J.Xu, D.G.Song, M.Poussin, Q.Ye, P.Sharma, A.Rodriguez-Garcia, Y.M.Tang, D.J.Powell. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. Oncotarget 2016; https://dx.doi.org/10.18632/oncotarget.10510
52. P.Carter, L.Presta, C.M.Gorman, J.B.Ridgway, D.Henner, W.L.Wong, A.M.Rowland, C.Kotts, M.E.Carver, H.M.Shepard. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
53. J.K.Peper, H.Schuster, M.W.Loffler, B.Schmid-Horch, H.G.Rammensee, S.Stevanovic. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods 2014; 405:192-8; PMID:24486140; http://dx.doi.org/10.1016/j.jim.2014.01.012